PET/MR in recurrent glioblastoma patients treated with regorafenib: [(18)F]FET and DWI-ADC for response assessment and survival prediction

OBJECTIVE: The use of regorafenib in recurrent glioblastoma patients has been recently approved by the Italian Medicines Agency (AIFA) and added to the National Comprehensive Cancer Network (NCCN) 2020 guidelines as a preferred regimen. Given its complex effects at the molecular level, the most appr...

Descripción completa

Detalles Bibliográficos
Autores principales: Lombardi, Giuseppe, Spimpolo, Alessandro, Berti, Sara, Campi, Cristina, Anglani, Maria Giulia, Simeone, Rossella, Evangelista, Laura, Causin, Francesco, Zorzi, Giovanni, Gorgoni, Giancarlo, Caccese, Mario, Padovan, Marta, Zagonel, Vittorina, Cecchin, Diego
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The British Institute of Radiology. 2022
Materias:
Full Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722234/
https://www.ncbi.nlm.nih.gov/pubmed/34762492
http://dx.doi.org/10.1259/bjr.20211018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722234/
https://www.ncbi.nlm.nih.gov/pubmed/34762492
http://dx.doi.org/10.1259/bjr.20211018

Ejemplares similares